Adding Patiromer Allows More Spironolactone in Resistant HTN, CKD

With or without heart failure, add-on treatment with the potassium sequestrant ‘enabled’ more intensive use of the aldosterone blocker otherwise limited by hyperkalemia, according to the AMBER trial.
Medscape Medical News

Source link

Related posts

Only 1 in 5 With High-Risk AF Leave ED on Anticoagulant


New Guidance to Optimize Antipsychotic Treatment


Teaching NeuroImages: Adolescent Wallenberg syndrome with overlooked signs: Ipsipulsion and ipsilateral facial palsy


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World